Pasithea Therapeutics Corporation has announced that it received a notice from the Nasdaq Stock Market on June 23, 2025, indicating non-compliance with the $1.00 minimum bid price requirement necessary for continued listing on the Nasdaq Capital Market. This notice does not lead to immediate delisting of the company's common stock. Pasithea has 180 calendar days, until December 22, 2025, to regain compliance by ensuring its stock closes at or above $1.00 per share for at least ten consecutive business days. The company is exploring options, including a potential reverse stock split, to address the issue. If compliance is not regained within this period, an additional 180-day period may be available, provided other listing criteria are met. Failure to comply could result in delisting, subject to appeal. This development does not affect the company's operations or SEC reporting requirements.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.